Login / Signup

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial.

Steven SilversteinElizabeth YeuJoseph TauberMichel GuillonLyndon JonesDavid GalarretaSruthi SrinivasanVenkiteshwar Manoj
Published in: Clinical ophthalmology (Auckland, N.Z.) (2020)
Our study demonstrated that PG-HPG nanoemulsion provided instant/immediate and sustained symptom relief for 8 hours post-single application and was well tolerated in patients with DED, demonstrated by their responses on each of the assessment scales.
Keyphrases
  • clinical trial
  • study protocol
  • patient reported
  • phase iii
  • randomized controlled trial
  • double blind